FR2619007A1 - Cosmetic preparations having a lipolytic action - Google Patents
Cosmetic preparations having a lipolytic action Download PDFInfo
- Publication number
- FR2619007A1 FR2619007A1 FR8711274A FR8711274A FR2619007A1 FR 2619007 A1 FR2619007 A1 FR 2619007A1 FR 8711274 A FR8711274 A FR 8711274A FR 8711274 A FR8711274 A FR 8711274A FR 2619007 A1 FR2619007 A1 FR 2619007A1
- Authority
- FR
- France
- Prior art keywords
- carnitine
- cosmetic preparations
- preparations according
- mitochondria
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 230000002366 lipolytic effect Effects 0.000 title abstract description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 30
- 229960004203 carnitine Drugs 0.000 claims abstract description 29
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 6
- 150000003839 salts Chemical group 0.000 claims abstract description 6
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims abstract description 5
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 229960000278 theophylline Drugs 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 150000004719 oxaloacetic acids Chemical class 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 210000003470 mitochondria Anatomy 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 9
- 108010051527 Carnitine Acyltransferases Proteins 0.000 description 7
- 102000013658 Carnitine Acyltransferases Human genes 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 4
- 229960001009 acetylcarnitine Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 3
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- -1 theophylline Chemical compound 0.000 description 3
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- GJTJQSPLLQWKMB-UHFFFAOYSA-N 3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentanoate Chemical class C(C)(=O)C(O)(C[N+](C)(C)C)CC([O-])=O GJTJQSPLLQWKMB-UHFFFAOYSA-N 0.000 description 1
- ZURLPLRYASEKGD-YXKORUMSSA-N 4-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-4-oxobutanoic acid 2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZURLPLRYASEKGD-YXKORUMSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000003207 subcutaneous adipocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
PREPARATIONS COSMETIQUES A ACTION LIPOLYTIQUE
L'invention concerne des préparations cosmetiques, et notamment des préparations cosinetiques présentant une activité lipolytique.COSMETIC PREPARATIONS WITH LIPOLYTIC ACTION
The invention relates to cosmetic preparations, and in particular to cosmetic preparations having lipolytic activity.
Elle a pour objet des préparations cosmétiques caractérisées en ce qu'elles comportent de la carnitine. It relates to cosmetic preparations characterized in that they contain carnitine.
Selon d'autres caractéristiques de l'invention
- La carnitine se présente sous la forme de l'isomère L ou du mélange racémique des isomères D et L
- La carnitine est présente sous forme libre.According to other features of the invention
- Carnitine comes in the form of the L isomer or the racemic mixture of the D and L isomers
- Carnitine is present in free form.
- La carnitine est présente sous forme de sel. - Carnitine is present in the form of salt.
- Le sel de carnitine est obtenu par réaction avec un acide du cycle de Krebs, à savoir l'un des acides citrique, isocitrique, a-cétoglutarique, succinique, fumarique, malique et oxaloacétique. - Carnitine salt is obtained by reaction with an acid from the Krebs cycle, namely one of the citric, isocitric, a-ketoglutaric, succinic, fumaric, malic and oxaloacetic acids.
- La carnitine est associée à une ou plusieurs méthylxanthines. - Carnitine is associated with one or more methylxanthines.
- L'une des méthylxanthines est la caféine ou ia théophylline. - One of the methylxanthines is caffeine or theophylline.
- Les préparations cosmétiques sont amincissantes. - Cosmetic preparations are slimming.
- Les préparations cosmétiques présentent en outre une activité énergisante, stimulante ou tonifiante. - Cosmetic preparations also have an energizing, stimulating or toning activity.
La carnitine, élément essentiel des préparations cosmétiques selon l'invention, a été isolée & partir d'extraits de viande dés 1905. On la trouve principalement dans le myocarde et les muscles squelettiques < 2-4 nmoles/mg de protéine), et également dans les tissus adipeux et le foie, ainsi qu'en beaucoup plus faible quantité, dans le plasma. Sa structure correspond à la formule
Il en existe deux isomères, D et L. Seul l'isomère L est présent dans la nature. There are two isomers, D and L. Only the L isomer occurs in nature.
La principale fonction de la carnitine est le transport des acides gras activés à longue chaîne du cytosol à l'intérieur des mitochondries, où sont situées les enzymes catalysant leur ss oxydation. The main function of carnitine is the transport of long chain activated fatty acids from the cytosol inside the mitochondria, where the enzymes catalyzing their oxidation are located.
Les acides gras présents dans le cytoplasme sont d'abord actives par une estérification avec du coen zyme A (CoA), en présence d'ATP, catalysée par des acylcoAsynthétases: Acides gras + ATP + CoAf ) acylCoA + AMP + PPi où ATP = adénosine tri phosphate, AMP = adénosine monophosphate,
PPi = pyrophosphate inorganique.The fatty acids present in the cytoplasm are first active by an esterification with coenyme A (CoA), in the presence of ATP, catalyzed by acylco Synthesis: Fatty acids + ATP + CoAf) acylCoA + AMP + PPi where ATP = adenosine tri phosphate, AMP = adenosine monophosphate,
PPi = inorganic pyrophosphate.
Cette réaction se produit dans le réticulum endoplasmique ou à la surface externe des mitochondries, où sont situées les acylCoAsynthetases. This reaction occurs in the endoplasmic reticulum or on the outer surface of the mitochondria, where the acylCoAsynthetases are located.
La membrane mitochondriale étant imperméable aux acylCoA, leur transport à l'intérieur de la mitochondrie est contrôlée par deux catégories d'enzymes carnitine-dépendantes : les carnitine acyl transférases et la carnitine translocase.The mitochondrial membrane being impermeable to acylCoA, their transport inside the mitochondria is controlled by two categories of carnitine-dependent enzymes: carnitine acyl transferases and carnitine translocase.
- les carnitine acyl transférases catalysent la réaction
acyl-CoA + L-carnltine=iacyl-carnitine + CoA
On connait trois catégories de carnitine acyl transférases, en fonction de la longueur de la chaîne carbonée de leur substrat
- la carnitine palmityl transférase
- la carnitine octanyl transférase
- la carnitine acétyl transferase.- carnitine acyl transferases catalyze the reaction
acyl-CoA + L-carnltine = iacyl-carnitine + CoA
We know three categories of carnitine acyl transferases, according to the length of the carbon chain of their substrate
- carnitine palmityl transferase
- carnitine octanyl transferase
- carnitine acetyl transferase.
La première, responsable du transport des acides gras A longue chaîne, existe sous deux forme : une, située à la surface externe de la membrane mîtochondriale interne < CATe), l'autre située a la surface interne (CATi). The first, responsible for the transport of long chain fatty acids, exists in two forms: one, located on the external surface of the internal miterochondrial membrane (CATe), the other located on the internal surface (CATi).
Bien que ces deux enzymes soient capables de catalyser la réaction dans les deux sens, la CATe la catalyse généralement dans le sens de la formation de l'acylcarnitine, tandis que la CATi catalyse préférentiellement la formation de l'acylCoA. Ces deux enzymes sont inhibées par un excès d'acylCoA a longue chaîne qui Jouent le rôle d'inhibiteurs compétitifs pour le second substrat, la carnitine. Contrairement à ces enzymes, la carnitine acétyl transférase est située uniquement à la surface interne de la membrane mitochondriale interne. De ce fait, elle joue le role de tampon du pool mitochondrial des acétyls : lorsque ceux-ci deviennent très abondants à l'intérieur de la mitochondrie, cette enzyme permet leur "excrétion" dans ie cytosol. Although these two enzymes are capable of catalyzing the reaction in both directions, CATe generally catalyzes it in the direction of the formation of acylcarnitine, while CATi preferentially catalyzes the formation of acylCoA. These two enzymes are inhibited by an excess of long chain acylCoA which play the role of competitive inhibitors for the second substrate, carnitine. Unlike these enzymes, carnitine acetyl transferase is located only on the inner surface of the inner mitochondrial membrane. As a result, it acts as a buffer for the mitochondrial pool of acetyls: when these become very abundant inside the mitochondria, this enzyme allows their "excretion" in the cytosol.
Le transport proprement dit à travers la membrane mitochondriale interne est assure par un système d'acylcarnitine translocase situé a l'extérieur de la membrane. Cette translocase échange l'acyl carnitine située à l'extérieur de la membrane contre de la carnitine interne ou, inversement, de l'acyl carnitine interne contre de la carnitine externe, dans un rapport rigoureusement stoechiométrique de 1 : 1. The actual transport through the internal mitochondrial membrane is ensured by an acylcarnitine translocase system located outside the membrane. This translocase exchanges the acyl carnitine located outside the membrane for internal carnitine or, conversely, internal acyl carnitine for external carnitine, in a strictly stoichiometric ratio of 1: 1.
La carnitine translocase assure donc la constance du pool de carnitine intramitochondrial en permettant un échange rapide avec la carnitine externe. The carnitine translocase therefore ensures the constancy of the intramitochondrial carnitine pool by allowing rapid exchange with the external carnitine.
En résumé, un acide gras à longue chaîne présent dans le cytosol est d'abord activé par formation d'acylCoA. Celui-ci est ensuite transformé en acyl carnitine par la CATe, permettant ainsi le franchissement de la membrane mitochondriale interne sous l'action de la carnitine translocase. In summary, a long chain fatty acid present in the cytosol is first activated by the formation of acylCoA. This is then transformed into acyl carnitine by CATe, thus allowing the internal mitochondrial membrane to be crossed under the action of carnitine translocase.
A l'intérieur de la mitochondrie, l'acyl carnitine est reconvertie en acylCoA par la CATi. Cet acylCoA peut alors subir la ss oxydation conduisant a ia formation d'acétylCoA incorporable dans le cycle de
Krebs.Inside the mitochondria, acyl carnitine is converted back to acylCoA by CATi. This acylCoA can then undergo ss oxidation leading to the formation of acetylCoA which can be incorporated into the
Krebs.
Le role physiologique essentiel de la Lcarnitine est donc de permettre le transport des acides gras à l'intérieur de la mitochondrie et, par conséquent leur ss oxydation. The essential physiological role of Lcarnitine is therefore to allow the transport of fatty acids inside the mitochondria and, consequently, their oxidation.
Cependant, la L-carnitine joue également un rôle régulateur dans le métabolisme. En effet, un excès d'acétylCoA à l'intérieur de la mitochondrie peut être transformé en acétyl carnitine par la carnitine acétyl transferase, puis excrété sous cette forme dans le cytosol. I1 en va de même, dans une certaine mesure, pour un exces d'acylCoA. Or, cette excrétion d'acyl et d'acétyl a pour conséquence un effet régulateur à la fois dans la mitochondrie et dans le cytosol
- dans la mitochondrie, il en résulte une libération de CoA qui etait auparavant bloqué sous forme d'acétylCoA ou d'acylCoA. Cette augmentation de la concentration intra-mitochondriale en CoA libre active la pyruvate déshydrogénase et par conséquent, la glycolyse.However, L-carnitine also plays a regulatory role in metabolism. Indeed, an excess of acetylCoA inside the mitochondria can be transformed into acetyl carnitine by the carnitine acetyl transferase, then excreted in this form in the cytosol. It is the same, to a certain extent, for an excess of acylCoA. However, this excretion of acyl and acetyl results in a regulatory effect both in the mitochondria and in the cytosol
- in the mitochondria, this results in a release of CoA which was previously blocked in the form of acetylCoA or acylCoA. This increase in the intra-mitochondrial concentration of free CoA activates pyruvate dehydrogenase and therefore glycolysis.
De plus, ce CoA libre peut également être utilisé dans la réaction : cétoglutarate succinylCoA, activant ainsi le cycle de Krebs. In addition, this free CoA can also be used in the reaction: ketoglutarate succinylCoA, thus activating the Krebs cycle.
- dans le cytosol, il se passe le phénomène inverse : une partie de l'acêtyl carnitine qui y pénètre est reconvertie en acétylcoA cytoplasmique, ce qui diminue la quantité de CoA libre disponible pour l'activation des acides gras par les acylCoAsynthétases et* par conséquent, freine la pénétration des acides gras dans la mitochondrie. En résumé, dans le cas d'un excès d'acétyl CoA ou d'acylCoA intramitochondrial, la carnitine permet à la fois d'augmenter le métabolisme et de freiner l'entrée de nouveaux acides gras dans la mitochondrie. Nais son rôle régulateur ne s'arrête pas la. Une partie des acides gras excrétés dans le cytosol reste liée a la carnitine sous forme d'acylcarnitine et d'acetylcarnitine.Dans le cas d'une surcharge trop importante, celles-ci peuvent passer dans le plasma sanguin et être éliminées par les reins. Par contre, dans le cas contraire d'une carence importante de la cellule en énergie, les acylcarnitines et acétylcarnitines stockées dans le cytoplasme constituent une réserve directement utilisable. Elles peuvent en effet être retransférées dans la mitochondrie et retransformées en acylCoA et en acétylCoA sans consommation d'énergie, tandis que l'oxydation du glucose ou d'acides gras nécessiterait l'utilisation préalable d'ATP pour la formation, respectivement, de fructose 1,6 diphosphate et d'acétylCoA. Cette fonction de l'acétyl carnitine est particulièrment importante au niveau du coeur où une seule pulsation consomme plus que la teneur intramitochondriale en acétylCoA existant à n'importe quei instant. - in the cytosol, the opposite phenomenon occurs: part of the acetyl carnitine which enters it is converted back into cytoplasmic acetylcoA, which decreases the amount of free CoA available for the activation of fatty acids by acylCoAsynthetases and * by Consequently, slows down the penetration of fatty acids into the mitochondria. In summary, in the case of an excess of acetyl CoA or intramitochondrial acylCoA, carnitine makes it possible both to increase the metabolism and to slow down the entry of new fatty acids into the mitochondria. But its regulatory role does not stop there. Part of the fatty acids excreted in the cytosol remains linked to carnitine in the form of acylcarnitine and acetylcarnitine. In the case of an excessive overload, these can pass into the blood plasma and be eliminated by the kidneys. On the other hand, in the opposite case of a significant deficiency of the cell in energy, the acylcarnitines and acetylcarnitines stored in the cytoplasm constitute a directly usable reserve. They can indeed be transferred back into the mitochondria and transformed back into acylCoA and acetylCoA without energy consumption, while the oxidation of glucose or fatty acids would require the prior use of ATP for the formation, respectively, of fructose 1.6 diphosphate and acetylCoA. This function of acetyl carnitine is particularly important in the heart where a single pulse consumes more than the intramitochondrial acetylCoA content existing at any time.
Dans ce qui précède sur le rôle métabolique de la L-carnîtine, . plusieurs points présentent un grand interét sur le plan cosmétique
- d'une part, la L-carnitine favorise l'élimination des lipides contenus dans les adipocytes sous-cutanés en activant la pénétration des acides gras dans les mitochondries et, par conséquent, leur ss oxydation.In the above on the metabolic role of L-carnitine,. several points are of great cosmetic interest
- on the one hand, L-carnitine promotes the elimination of lipids contained in subcutaneous adipocytes by activating the penetration of fatty acids into the mitochondria and, consequently, their ss oxidation.
- d'autre part, les acides gras ainsi métabolisés peuvent constituer un substrat, et donc un apport d'énergie directement utilisable par les cellules dermiques et épidermiques. - on the other hand, the fatty acids thus metabolized can constitute a substrate, and therefore an energy supply directly usable by the dermal and epidermal cells.
Les préparations cosmétiques comportant de la carnitine conformément å l'invention présentent une activité lipolytique qui les rend utilisables comme préparations cométiques amincissantes. Cette activite est accrue par l'association å la carnitine d'une méthylxanthine comme la théophylline, qui agit en bloquant la phosphodiestèrase. Cosmetic preparations comprising carnitine in accordance with the invention have a lipolytic activity which makes them usable as slimming cometic preparations. This activity is increased by the association with carnitine of a methylxanthine like theophylline, which acts by blocking phosphodiesterase.
Il faut remarquer que seule la L-carnitine est physiologiquement active. On peut utiliser la Lcarnitine ou la DL-carnitine < mélange racémique de deux isomères) mais un apport de D-carnitine peut induire une diminution de la teneur en L-carnitine du sérum et des organes. It should be noted that only L-carnitine is physiologically active. You can use Lcarnitine or DL-carnitine (racemic mixture of two isomers) but an intake of D-carnitine can induce a decrease in the L-carnitine content of serum and organs.
Il résulte de ce qui précède que la DL ou la Lcarnitine peuvent etre utilisées avantageusement en cosmétique, par exemple pour la préparation de produits amincissants, ou comme compléments dans des produits énergisants, tonifiants ou stimulants. It follows from the above that DL or Lcarnitine can be used advantageously in cosmetics, for example for the preparation of slimming products, or as supplements in energizing, toning or stimulating products.
La carnitine peut être utilisée soit sous sa forme libre, soit sousforme Ae sels. Ces sels peuvent être obtenus en faisant réagir la carnitine avec un acide qui pourra avantageusement etre choisi parmi les acides intervenant dans le cycle de Krebs, à savoir le acides citrique, isocitrique, a-cétoglutarique, succinique, fumarique, malique et oxaloacétique. De manière à augmenter l'activité lipolytique de la préparation renfermant la carnitine, on peut également lui associer une substance inhibant la phosphodiestérase telie que, par exempie, les méthylxanthines (caféine, théophylline...). Carnitine can be used either in its free form or in the form of salts. These salts can be obtained by reacting carnitine with an acid which can advantageously be chosen from the acids involved in the Krebs cycle, namely citric, isocitric, a-ketoglutaric, succinic, fumaric, malic and oxaloacetic acids. In order to increase the lipolytic activity of the preparation containing carnitine, it is also possible to associate a substance inhibiting phosphodiesterase such as, for example, methylxanthines (caffeine, theophylline, etc.).
Des exemples de préparations cosmétiques selon l'invention sont mentionnés ci-dessous. Examples of cosmetic preparations according to the invention are mentioned below.
Exemple 1 : crème amincissante
Palmitate de cétyle i
Stéarine 3
Alcool cétylique 2
Huile minérale 10 %
Nyristate d'isopropyle 7
Triéthanolamine 0,85 %
Conservateurs- 0,3 %
Parfum 0.3 %
L-Carnitine 1
Eau déminéralisée qsp 100%
Exemple 2 : crème amincissante Sesquioléate de sorbitan 3
Acide Stéarique 3,5 %
Alcool cétylique 1,5 %
Huile minérale 15 %
Triéthanolamine 0,8 %
Sorbitol 4 %
Conservateurs 0,3 %
Parfum 0,3 % Fumarate de L-Carnitine 2 %
Eau déminéralisée qsp 100 %
Exemple 3 : gel amincissant
Stéarate de glycérol 2
Cire d'abeille 0,75 %
Myristate d'isopropyle 2 %
Huile minérale 5 /,
Mélange d'acides carboxyvinyliques commercialisés sous la marque Carbopoi 940 0,2 %
Triéthanolamine 0,25 eb
Propylène glycol 5
Conservateurs 0,3 %
Parfum 0,3 %
Fumarate de L-Carnitine 0,8 %
Caféine 0,5 %
Eau déminéralisée qsp 100 %
Exemple 4 : lotion énergisante
Propylème glycol 5 %
Glycérine 3 %
Parfum 0,2 %
Conservateurs 0,3 %
Citrate de DL-Carnitine 1 %
Extrait protéolysé de rate bovine 3 %
Eau déminéralisée qsp 100 %
Exemple 5 : soluté tonifiant pour ampoules cosmetiques
Glycérine 10 %
Propylène glycol 10 %
Conservateurs G,3 %
L-Carnitine 1 %
Albumine bovine 2
Eau déminéralisée qsp 100 % Example 1: slimming cream
Cetyl palmitate i
Stearin 3
Cetyl alcohol 2
10% mineral oil
Isopropyl Nyristate 7
Triethanolamine 0.85%
Preservatives - 0.3%
Perfume 0.3%
L-Carnitine 1
Demineralized water qs 100%
EXAMPLE 2 Slimming Cream Sesquioleate of Sorbitan 3
Stearic Acid 3.5%
Cetyl alcohol 1.5%
Mineral oil 15%
0.8% triethanolamine
Sorbitol 4%
Preservatives 0.3%
Perfume 0.3% L-Carnitine Fumarate 2%
Demineralized water qs 100%
EXAMPLE 3 Slimming Gel
Glycerol stearate 2
Beeswax 0.75%
Isopropyl myristate 2%
Mineral oil 5 /,
Mixture of carboxyvinyl acids sold under the Carbopoi 940 brand 0.2%
0.25 triethanolamine eb
Propylene glycol 5
Preservatives 0.3%
Perfume 0.3%
0.8% L-Carnitine fumarate
Caffeine 0.5%
Demineralized water qs 100%
EXAMPLE 4 Energizing Lotion
Propylem glycol 5%
Glycerin 3%
0.2% fragrance
Preservatives 0.3%
DL-Carnitine Citrate 1%
3% bovine spleen proteolysed extract
Demineralized water qs 100%
Example 5: toning solution for cosmetic ampoules
Glycerin 10%
Propylene glycol 10%
Preservatives G, 3%
L-Carnitine 1%
Bovine albumin 2
Demineralized water qs 100%
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8711274A FR2619007B1 (en) | 1987-08-07 | 1987-08-07 | COSMETIC PREPARATIONS WITH LIPOLYTIC ACTION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8711274A FR2619007B1 (en) | 1987-08-07 | 1987-08-07 | COSMETIC PREPARATIONS WITH LIPOLYTIC ACTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2619007A1 true FR2619007A1 (en) | 1989-02-10 |
| FR2619007B1 FR2619007B1 (en) | 1990-09-28 |
Family
ID=9354021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8711274A Expired - Fee Related FR2619007B1 (en) | 1987-08-07 | 1987-08-07 | COSMETIC PREPARATIONS WITH LIPOLYTIC ACTION |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2619007B1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694195A1 (en) * | 1992-07-30 | 1994-02-04 | Sederma Sa | Compsns. for removing subcutaneous fat - contg. coenzyme A, carnitine and caffeine |
| US6372791B1 (en) | 2000-06-29 | 2002-04-16 | Johnson & Johnson Consumer Companies, Inc. | Method of promoting skin cell metabolism |
| US6432424B1 (en) | 2000-06-29 | 2002-08-13 | Johnson & Johnson Consumer Companies, Inc. | Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid |
| US6630175B1 (en) | 2000-06-29 | 2003-10-07 | Johnson & Johnson Consumer Companies, Inc. | Method of reducing eye irritation |
| US6649176B1 (en) | 2000-06-29 | 2003-11-18 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing mineral water |
| WO2004074216A3 (en) * | 2003-02-21 | 2004-11-04 | Vama Farmacosmetica S R L | Carnitine salt, preliposome which contains it and dermo-cosmetic formula for topical use based upon said carnitine salt |
| WO2005115326A1 (en) * | 2004-05-31 | 2005-12-08 | Showa Denko K.K. | Topical slimming preparation and a cosmetic containing a carnitine derivative |
| WO2006013082A1 (en) * | 2004-08-04 | 2006-02-09 | Vama Farmacosmetica S.R.L. | 1-carnitine-based cosmetic raw material for a preparation with long-lasting moisturising effect, and cosmetic preparation obtained with this raw material |
| WO2008138393A1 (en) * | 2007-05-11 | 2008-11-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of cosmetic active ingredients |
| EP1827360A4 (en) * | 2004-12-21 | 2009-03-04 | Avon Prod Inc | Cosmetic compositions having carnitine creatinate and methods for using |
| WO2009046819A3 (en) * | 2007-10-01 | 2009-08-06 | Beiersdorf Ag | Method for reducing signs of ageing on skin |
| JP2022509273A (en) * | 2018-12-20 | 2022-01-20 | ロレアル | A method for treating keratin fibers using a composition comprising a carnitine salt containing an aliphatic dicarboxylic acid anion or a carnitine derivative salt. |
| US12409122B2 (en) | 2018-12-20 | 2025-09-09 | L'oreal | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aromatic organic anion |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4465M (en) * | 1965-06-28 | 1966-09-26 | ||
| FR2144567A1 (en) * | 1971-07-06 | 1973-02-16 | Labaz | |
| DE2323906A1 (en) * | 1972-05-11 | 1973-11-22 | Beecham Group Ltd | PHARMACEUTICAL PREPARATION AGAINST OBESITY |
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| GB2013496A (en) * | 1978-02-03 | 1979-08-15 | Sigma Tau Ind Farmaceuti | Treating hyperlipoproteinaemias and hyperlipidaemias |
| EP0150688A1 (en) * | 1983-12-28 | 1985-08-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Salts of L-carnitine and alkanoyl L-carnitines and process for preparing same |
-
1987
- 1987-08-07 FR FR8711274A patent/FR2619007B1/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4465M (en) * | 1965-06-28 | 1966-09-26 | ||
| FR2144567A1 (en) * | 1971-07-06 | 1973-02-16 | Labaz | |
| DE2323906A1 (en) * | 1972-05-11 | 1973-11-22 | Beecham Group Ltd | PHARMACEUTICAL PREPARATION AGAINST OBESITY |
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| GB2013496A (en) * | 1978-02-03 | 1979-08-15 | Sigma Tau Ind Farmaceuti | Treating hyperlipoproteinaemias and hyperlipidaemias |
| EP0150688A1 (en) * | 1983-12-28 | 1985-08-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Salts of L-carnitine and alkanoyl L-carnitines and process for preparing same |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 82, no. 1, 6 janvier 1975, page 197, résumé no. 2134p, Columbus, Ohio, US; M. NOVAK et al.: "Effect of carnitine on lipolysis in subcutaneous adipose tissue of newborns", & BIOL. NEONATE 1975, 25(1-2), 85-94 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694195A1 (en) * | 1992-07-30 | 1994-02-04 | Sederma Sa | Compsns. for removing subcutaneous fat - contg. coenzyme A, carnitine and caffeine |
| US6372791B1 (en) | 2000-06-29 | 2002-04-16 | Johnson & Johnson Consumer Companies, Inc. | Method of promoting skin cell metabolism |
| US6432424B1 (en) | 2000-06-29 | 2002-08-13 | Johnson & Johnson Consumer Companies, Inc. | Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid |
| EP1166763B1 (en) * | 2000-06-29 | 2003-03-05 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid |
| US6630175B1 (en) | 2000-06-29 | 2003-10-07 | Johnson & Johnson Consumer Companies, Inc. | Method of reducing eye irritation |
| US6649176B1 (en) | 2000-06-29 | 2003-11-18 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing mineral water |
| WO2004074216A3 (en) * | 2003-02-21 | 2004-11-04 | Vama Farmacosmetica S R L | Carnitine salt, preliposome which contains it and dermo-cosmetic formula for topical use based upon said carnitine salt |
| WO2005115326A1 (en) * | 2004-05-31 | 2005-12-08 | Showa Denko K.K. | Topical slimming preparation and a cosmetic containing a carnitine derivative |
| WO2006013082A1 (en) * | 2004-08-04 | 2006-02-09 | Vama Farmacosmetica S.R.L. | 1-carnitine-based cosmetic raw material for a preparation with long-lasting moisturising effect, and cosmetic preparation obtained with this raw material |
| EP1827360A4 (en) * | 2004-12-21 | 2009-03-04 | Avon Prod Inc | Cosmetic compositions having carnitine creatinate and methods for using |
| WO2008138393A1 (en) * | 2007-05-11 | 2008-11-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of cosmetic active ingredients |
| AU2007353211B2 (en) * | 2007-05-11 | 2013-08-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of cosmetic active ingredients |
| WO2009046819A3 (en) * | 2007-10-01 | 2009-08-06 | Beiersdorf Ag | Method for reducing signs of ageing on skin |
| JP2022509273A (en) * | 2018-12-20 | 2022-01-20 | ロレアル | A method for treating keratin fibers using a composition comprising a carnitine salt containing an aliphatic dicarboxylic acid anion or a carnitine derivative salt. |
| US12390406B2 (en) | 2018-12-20 | 2025-08-19 | L'oreal | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aliphatic dicarboxylic acid anion |
| US12409122B2 (en) | 2018-12-20 | 2025-09-09 | L'oreal | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aromatic organic anion |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2619007B1 (en) | 1990-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Driedzic et al. | Metabolism in fish during exercise | |
| FR2619007A1 (en) | Cosmetic preparations having a lipolytic action | |
| Acheson et al. | Nutritional influences on lipogenesis and thermogenesis after a carbohydrate meal | |
| Chatzifotis et al. | The effcet of dietary L-carnitine on growth performance and lipid composition in red sea bream fingerlings | |
| US4058594A (en) | Immuno-suppressive agents | |
| EP0414605B1 (en) | Pasty aqueous pharmaceutical compositions | |
| JP2873497B2 (en) | Lipid metabolism regulator | |
| CA2136706C (en) | Process for controlling adiposity and compositions for use therein | |
| Alonso et al. | Participation of ornithine aminotransferase in the synthesis and catabolism of ornithine in mice. Studies using gabaculine and arginine deprivation | |
| JP2002542191A (en) | Carnitine and glutathione-containing compositions useful for increasing glutathione absorption and enhancing its effect | |
| GB1580444A (en) | Pharmaceutical compositions | |
| Hayashi et al. | Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction | |
| US6743821B2 (en) | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | |
| Parola et al. | 4-hydroxy-2, 3-alkenals as molecular mediators of oxidative stress in the pathogenesis of liver fibrosis | |
| Thayer | Inhibition of mitochondrial fatty acid oxidation in pentenoic acid-induced fatty liver: a possible model for Reye's syndrome | |
| Yang et al. | HEMODYNAMIC AND METABOLIC-ACTIVITIES OF PROPIONYL-L-CARNITINE IN RATS WITH PRESSURE-OVERLOAD CARDIAC-HYPERTROPHY | |
| FR2711529A1 (en) | Composition based on amino acids intended for the treatment of an infection or an aggression causing an inflammatory reaction, in animals and in humans. | |
| Henley et al. | The effect of oral ethanol on glutamic pyruvic and glutamic oxalacetic transaminase activity in the rat liver | |
| FR2556593A1 (en) | NUTRIENT COMPOSITION CONTAINING ALPHA-KETOOCOPROIC ACID, LEUCINE AND ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS | |
| Rodgers et al. | Insulin-like effects of a physiologic concentration of carnitine on cardiac metabolism | |
| Krähenbühl et al. | Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis | |
| JP5921747B2 (en) | Ceramide and collagen synthesis promoter and collagen saccharification inhibitor | |
| Ballantyne et al. | Osmotic effects on fatty acid, pyruvate, and ketone body oxidation in oyster gill mitochondria | |
| KR100693628B1 (en) | Improvement of alcohol metabolism | |
| MC2394A1 (en) | Composition intended to stop the fall and / or to promote |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CD | Change of name or company name | ||
| TP | Transmission of property | ||
| ST | Notification of lapse |